Health Care Archives - Page 454 of 478

2 minute read

Alnylam Shares Shoot Higher Following Positive Clinical Results From Late-Stage ATTR Amyloidosis Therapeutics

August 3, 10:44 AM

Alnylam (NASDAQ: ALNY) announced positive results from the APOLLO-B Phase 3 study of Patisiran for the treatment of transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy.

ALNY

1 minute read

FDA Accepts MediWound’s Refiling For Severe Thermal Burns Therapy For Review

By Ragothaman Srinivasan

August 3, 10:22 AM

The U.S. Food and Drug Administration (FDA) has accepted for review MediWound’s (NASDAQ: MDWD) recently re-submitted Biologics License Application (BLA) for its lead asset NexoBrid for eschar removal (debridement) in adults with deep partial-thickness and/or full-thickness thermal burns.

MDWD

1 minute read

Kiniksa Inks Global License Agreement With Roche For Vixarelimab

By Vandana Singh

August 3, 9:40 AM

Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) has announced a global license agreement with Roche Holdings AG (OTC:RHHBY) and Genentech to develop and commercialize vixarelimab, a fully human…

KNSA

1 minute read

Merck’s Two Keytruda Combo Cancer Trials Miss Primary Goal

By Vandana Singh

August 3, 8:53 AM

Merck & Co Inc’s (NYSE:MRK) Phase 3 KEYNOTE-921 trial of Keytruda combined with chemotherapy (docetaxel) did not meet its dual…

ESALF

1 minute read

CVS Health Q2 Sales Up Across Insurance & Pharmacy, Lifts Annual Outlook

By Vandana Singh

August 3, 8:19 AM

CVS Health Corp’s (NYSE:CVS) Q2 sales increased 11% Y/Y to $80.6 billion, beating the consensus of $76.37 billion. Prescriptions filled…

CVS

2 minute read

Recap Of Tuesday’s Biotech Catalysts – End Of the Day Summary

By Ragothaman Srinivasan

August 2, 6:39 PM

Avalo Therapeutics (NASDAQ:AVTX) has dosed the first patient in the pivotal LADDER trial to assess the efficacy and…

AVTX

1 minute read

Neuromodulation Focused Company Axonics Gets 28% Price Target Bump By This Analyst On Solid Q2 Performance

By Vandana Singh

August 2, 1:58 PM

Axonics Inc (NASDAQ:AXNX) reported a 50% Y/Y increase in Q2 sales to $69 million, beating the consensus of $59 million.…

AXNX

1 minute read

Emergent BioSolutions Posts Q2 Loss On Lower Sales, Q3 Forecasts Below Consensus

By Vandana Singh

August 2, 1:50 PM

Emergent BioSolutions Inc’s (NYSE: EBS) Q2 sales fell 39% Y/Y to $242.7 million, missing the consensus of $270.94 million. Revenues from…

AZN

1 minute read

Rhythm Pharma Outlines Robust Start To Newly Approved Drug For Genetic Condition

By Vandana Singh

August 2, 1:46 PM

Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) announced that over 35 physicians have written 50+ prescriptions for Imcivree (setmelanotide) for Bardet-Biedl syndrome…

RYTM

1 minute read

Vaxxinity’s Vaccine Candidate Shows Durable Cholesterol Lowering Activity In Animal Models

By Vandana Singh

August 2, 1:43 PM

Vaxxinity Inc (NASDAQ:VAXX) announced data demonstrating durable lowering of low-density lipoprotein (LDL) cholesterol in non-human primates. The company also selected VXX-401…

VAXX